pMPA Technology

pMPA Technology. All rights in all data, technology, know how, patents, copyrights, marks, trade secrets and other intellectual property owned, used or licensed (as licensor or licensee) by Assignor or its predecessors-in-interest (including but not limited to, all improvements, changes and modifications thereto that at any time in the past were, or currently are, in the process of being made, tested or developed) in connection with (a) a polymerized version of mycophenolate ("p-MPA") with expected resorption... of orally administered p-MPA in a suitable dosage form in the gastrointestinal tract to provide steady and prolonged levels of the active principle mycophenolate ("MPA") in the bloodstream; (b) plans to design p-MPA, by varying certain parameters such as degree of polymerization, chemical nature of the linker molecule, or controlling the particle size of the drug product, so that it exhibits pharmacokinetic properties suitable for once-a-day, or less frequent dosing, providing certain convenience advantages over mycophenolate (dosed twice or thrice-a-day), including, but not limited to, all experimental plans, development plans, regulatory strategies, marketing plans and competitive analyses therefor, (c) any business plans for such technology, (d) any developmental strategy designed in the indication pemphigus vulgaris, a rare, dermal autoimmune disease for which there is no causual treatment, and (e) any marketing plans. View More